183 related articles for article (PubMed ID: 35534342)
41. Incremental value of radiomics-based heterogeneity to the existing risk criteria in predicting recurrence of hepatocellular carcinoma after liver transplantation.
Nie P; Zhang J; Miao W; Duan S; Wang T; Zhang J; Gu J; Wang N; Zhang R; Wang X; Yang G; Rao W; Wang Z
Eur Radiol; 2023 Sep; 33(9):6608-6618. PubMed ID: 37012548
[TBL] [Abstract][Full Text] [Related]
42. Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation.
Andreou A; Bahra M; Schmelzle M; Öllinger R; Sucher R; Sauer IM; Guel-Klein S; Struecker B; Eurich D; Klein F; Pascher A; Pratschke J; Seehofer D
Clin Transplant; 2016 Jul; 30(7):819-27. PubMed ID: 27107252
[TBL] [Abstract][Full Text] [Related]
43. Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis.
Wong LL; Naugler WE; Schwartz J; Scott DL; Bhattacharya R; Reyes J; Orloff SL
Clin Transplant; 2013; 27(1):E72-9. PubMed ID: 23278701
[TBL] [Abstract][Full Text] [Related]
44. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
[TBL] [Abstract][Full Text] [Related]
45. The survival benefit of liver transplantation for hepatocellular carcinoma patients with hepatitis B virus infection and cirrhosis.
Zhang Q; Chen X; Zang Y; Zhang L; Chen H; Wang L; Niu Y; Ren X; Shen Z; Shang L
PLoS One; 2012; 7(12):e50919. PubMed ID: 23236406
[TBL] [Abstract][Full Text] [Related]
46. Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation.
Teng F; Wang GH; Tao YF; Guo WY; Wang ZX; Ding GS; Shi XM; Fu ZR
World J Gastroenterol; 2014 Aug; 20(31):10900-7. PubMed ID: 25152592
[TBL] [Abstract][Full Text] [Related]
47. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
48. Risk Factors for Hepatocellular Carcinoma Recurrence and Survival after Liver Transplantation in Patients with HCV-Related Cirrhosis.
Vidal RIO; Vidal EIO; Pereira BB; Assane CC; Ribeiro A; do Nascimento EM; Romeiro FG; Ribeiro Filho J
Biomed Res Int; 2020; 2020():1487593. PubMed ID: 33134370
[TBL] [Abstract][Full Text] [Related]
49. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
Fernandez-Sevilla E; Allard MA; Selten J; Golse N; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Adam R
Liver Transpl; 2017 Apr; 23(4):440-447. PubMed ID: 28187493
[TBL] [Abstract][Full Text] [Related]
50. Post-transplant inflammatory cytokine signature adds value for predicting tumor recurrence after liver transplantation for hepatocellular carcinoma.
Ng KT; Liu J; Yeung OW; Pang L; Shiu HC; Liu H; Yang XX; Chan AC; Wong TC; Lo CM; Man K
Hepatol Int; 2023 Dec; 17(6):1596-1609. PubMed ID: 37542605
[TBL] [Abstract][Full Text] [Related]
51. Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation.
Zhang Q; Deng YL; Liu C; Huang LH; Shang L; Chen XG; Wang LT; Du JZ; Wang Y; Wang PX; Zhang H; Shen ZY
World J Gastroenterol; 2016 Nov; 22(43):9571-9585. PubMed ID: 27920478
[TBL] [Abstract][Full Text] [Related]
52. Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.
Tran BV; Moris D; Markovic D; Zaribafzadeh H; Henao R; Lai Q; Florman SS; Tabrizian P; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Hoteit M; Levine MH; Cillo U; Vitale A; Verna EC; Halazun KJ; Tevar AD; Humar A; Chapman WC; Vachharajani N; Aucejo F; Lerut J; Ciccarelli O; Nguyen MH; Melcher ML; Viveiros A; Schaefer B; Hoppe-Lotichius M; Mittler J; Nydam TL; Markmann JF; Rossi M; Mobley C; Ghobrial M; Langnas AN; Carney CA; Berumen J; Schnickel GT; Sudan DL; Hong JC; Rana A; Jones CM; Fishbein TM; Busuttil RW; Barbas AS; Agopian VG
Liver Transpl; 2023 Jul; 29(7):683-697. PubMed ID: 37029083
[TBL] [Abstract][Full Text] [Related]
53. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient.
Nissen NN; Menon V; Bresee C; Tran TT; Annamalai A; Poordad F; Fair JH; Klein AS; Boland B; Colquhoun SD
HPB (Oxford); 2011 Sep; 13(9):626-32. PubMed ID: 21843263
[TBL] [Abstract][Full Text] [Related]
54. Preoperative Alfa-Fetoprotein and Fibrinogen Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation Regardless of the Milan Criteria: Model Development with External Validation.
Jiang N; Zeng KN; Dou KF; Lv Y; Zhou J; Li HB; Tang JX; Li JJ; Wang GY; Yi SH; Yi HM; Li H; Chen GH; Yang Y
Cell Physiol Biochem; 2018; 48(1):317-327. PubMed ID: 30016765
[TBL] [Abstract][Full Text] [Related]
55. The predictive value of the modified AFP model for liver transplantation outcomes in multinodular hepatocellular carcinoma patients.
Wang J; Bao J; Wang R; Hong J; Zhang L; Que Q; Xu S; Wu Y; Zhan Q; Liu Y; Liu J; Zheng S; Ling S; Xu X
World J Surg Oncol; 2023 Mar; 21(1):104. PubMed ID: 36967432
[TBL] [Abstract][Full Text] [Related]
56. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
[TBL] [Abstract][Full Text] [Related]
57. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
58. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation.
Guerrini GP; Pinelli D; Marini E; Corno V; Guizzetti M; Zambelli M; Aluffi A; Lincini L; Fagiuoli S; Lucianetti A; Colledan M
Prog Transplant; 2018 Mar; 28(1):63-69. PubMed ID: 29251164
[TBL] [Abstract][Full Text] [Related]
59. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.
Lei JY; Yan LN; Wang WT
World J Gastroenterol; 2013 Jul; 19(27):4400-8. PubMed ID: 23885153
[TBL] [Abstract][Full Text] [Related]
60. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience.
Bonadio I; Colle I; Geerts A; Smeets P; Berardi G; Praet M; Rogiers X; de Hemptinne B; Van Vlierberghe H; Troisi RI
Clin Transplant; 2015 May; 29(5):425-33. PubMed ID: 25808782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
